Sandoz Group AG Expands US Market Presence with Biosimilar Launch

Sandoz Group AG, a pharmaceutical company based in Switzerland, has launched interchangeable denosumab biosimilars, WYOST and Jubbonti, in the US market.

• The launch provides new treatment options for patients suffering from osteoporosis and cancer-related skeletal events.
• The affected patient population exceeds 10 million individuals.

Key Highlights:

• The launch solidifies Sandoz’s position as a global leader in biosimilars and oncology.
• The development expands access to treatment for a substantial patient base.

Market Impact:

• The launch is expected to have a positive impact on Sandoz’s market presence.
• The company’s commitment to making high-quality medicines accessible has been reinforced by this development.